|
1
|
Aggarwal N, Yadav J, Chhakara S, Janjua D, Tripathi T, Chaudhary A, Chhokar A, Thakur K, Singh T, Bharti AC. Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus-Driven Head and Neck Cancer: Current Evidence and Future Prospects. Front Pharmacol 2021; 12:699044. [PMID: 34354591 PMCID: PMC8329252 DOI: 10.3389/fphar.2021.699044] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 06/17/2021] [Indexed: 12/20/2022] Open
Abstract
Head and neck cancer (HNC) usually arises from squamous cells of the upper aerodigestive tract that line the mucosal surface in the head and neck region. In India, HNC is common in males, and it is the sixth most common cancer globally. Conventionally, HNC attributes to the use of alcohol or chewing tobacco. Over the past four decades, portions of human papillomavirus (HPV)-positive HNC are increasing at an alarming rate. Identification based on the etiological factors and molecular signatures demonstrates that these neoplastic lesions belong to a distinct category that differs in pathological characteristics and therapeutic response. Slow development in HNC therapeutics has resulted in a low 5-year survival rate in the last two decades. Interestingly, HPV-positive HNC has shown better outcomes following conservative treatments and immunotherapies. This raises demand to have a pre-therapy assessment of HPV status to decide the treatment strategy. Moreover, there is no HPV-specific treatment for HPV-positive HNC patients. Accumulating evidence suggests that phytochemicals are promising leads against HNC and show potential as adjuvants to chemoradiotherapy in HNC. However, only a few of these phytochemicals target HPV. The aim of the present article was to collate data on various leading phytochemicals that have shown promising results in the prevention and treatment of HNC in general and HPV-driven HNC. The review explores the possibility of using these leads against HPV-positive tumors as some of the signaling pathways are common. The review also addresses various challenges in the field that prevent their use in clinical settings.
Collapse
Affiliation(s)
- Nikita Aggarwal
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Joni Yadav
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Suhail Chhakara
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Divya Janjua
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Tanya Tripathi
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Apoorva Chaudhary
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Arun Chhokar
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Kulbhushan Thakur
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Tejveer Singh
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| | - Alok Chandra Bharti
- Molecular Oncology Laboratory, Department of Zoology, Faculty of Science, University of Delhi, Delhi, India
| |
Collapse
|
|
2
|
Peñate Medina T, Gerle M, Humbert J, Chu H, Köpnick AL, Barkmann R, Garamus VM, Sanz B, Purcz N, Will O, Appold L, Damm T, Suojanen J, Arnold P, Lucius R, Willumeit-Römer R, Açil Y, Wiltfang J, Goya GF, Glüer CC, Peñate Medina O. Lipid-Iron Nanoparticle with a Cell Stress Release Mechanism Combined with a Local Alternating Magnetic Field Enables Site-Activated Drug Release. Cancers (Basel) 2020; 12:cancers12123767. [PMID: 33327621 PMCID: PMC7765112 DOI: 10.3390/cancers12123767] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 12/02/2020] [Accepted: 12/02/2020] [Indexed: 11/16/2022] Open
Abstract
Most available cancer chemotherapies are based on systemically administered small organic molecules, and only a tiny fraction of the drug reaches the disease site. The approach causes significant side effects and limits the outcome of the therapy. Targeted drug delivery provides an alternative to improve the situation. However, due to the poor release characteristics of the delivery systems, limitations remain. This report presents a new approach to address the challenges using two fundamentally different mechanisms to trigger the release from the liposomal carrier. We use an endogenous disease marker, an enzyme, combined with an externally applied magnetic field, to open the delivery system at the correct time only in the disease site. This site-activated release system is a novel two-switch nanomachine that can be regulated by a cell stress-induced enzyme at the cellular level and be remotely controlled using an applied magnetic field. We tested the concept using sphingomyelin-containing liposomes encapsulated with indocyanine green, fluorescent marker, or the anticancer drug cisplatin. We engineered the liposomes by adding paramagnetic beads to act as a receiver of outside magnetic energy. The developed multifunctional liposomes were characterized in vitro in leakage studies and cell internalization studies. The release system was further studied in vivo in imaging and therapy trials using a squamous cell carcinoma tumor in the mouse as a disease model. In vitro studies showed an increased release of loaded material when stress-related enzyme and magnetic field was applied to the carrier liposomes. The theranostic liposomes were found in tumors, and the improved therapeutic effect was shown in the survival studies.
Collapse
Affiliation(s)
- Tuula Peñate Medina
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
- Institute for Experimental Cancer Research, Christian-Albrechts-University Kiel, 24105 Kiel, Germany;
| | - Mirko Gerle
- Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (M.G.); (H.C.); (N.P.); (Y.A.); (J.W.)
| | - Jana Humbert
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
| | - Hanwen Chu
- Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (M.G.); (H.C.); (N.P.); (Y.A.); (J.W.)
- Department of Oral and Maxillofacial Surgery, Second Affiliated Hospital, Zhejiang University, Hangzhou 310058, China
| | - Anna-Lena Köpnick
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
- Institute for Experimental Cancer Research, Christian-Albrechts-University Kiel, 24105 Kiel, Germany;
| | - Reinhard Barkmann
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
| | - Vasil M. Garamus
- Helmholtz-Zentrum Geesthacht, Zentrum für Material- und Küstenforschung GmbH, Max Planck Straße 1, 21502 Geesthacht, Germany; (V.M.G.); (R.W.-R.)
| | - Beatriz Sanz
- Institute of Nanoscience of Aragon (INA) and Condensed Matter Physics Dept., University of Zaragoza, C.P. 50.018 Zaragoza, Spain; (B.S.); (G.F.G.)
| | - Nicolai Purcz
- Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (M.G.); (H.C.); (N.P.); (Y.A.); (J.W.)
| | - Olga Will
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
| | - Lia Appold
- Institute for Experimental Cancer Research, Christian-Albrechts-University Kiel, 24105 Kiel, Germany;
| | - Timo Damm
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
| | - Juho Suojanen
- Cleft Palate and Craniofacial Center, Department of Plastic Surgery, Helsinki University Hospital, 00029 HUS Helsinki, Finland;
- Päijät-Häme Joint Authority for Health and Wellbeing, Department of Oral and Maxillo-Facial Surgery, 15850 Lahti, Finland
| | - Philipp Arnold
- Anatomical Institute, Christian-Albrechts-University Kiel, 24105 Kiel, Germany or (P.A.); (R.L.)
| | - Ralph Lucius
- Anatomical Institute, Christian-Albrechts-University Kiel, 24105 Kiel, Germany or (P.A.); (R.L.)
| | - Regina Willumeit-Römer
- Helmholtz-Zentrum Geesthacht, Zentrum für Material- und Küstenforschung GmbH, Max Planck Straße 1, 21502 Geesthacht, Germany; (V.M.G.); (R.W.-R.)
| | - Yahya Açil
- Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (M.G.); (H.C.); (N.P.); (Y.A.); (J.W.)
| | - Joerg Wiltfang
- Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (M.G.); (H.C.); (N.P.); (Y.A.); (J.W.)
| | - Gerardo F. Goya
- Institute of Nanoscience of Aragon (INA) and Condensed Matter Physics Dept., University of Zaragoza, C.P. 50.018 Zaragoza, Spain; (B.S.); (G.F.G.)
| | - Claus C. Glüer
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
| | - Oula Peñate Medina
- Section Biomedical Imaging, Department of Radiology and Neuroradiology Universitätsklinikum Schleswig-Holstein Campus Kiel, Christian Albrechts Universität zu Kiel, 24105 Kiel, Germany; (T.P.M.); (J.H.); (A.-L.K.); (R.B.); (O.W.); (T.D.); (C.C.G.)
- Institute for Experimental Cancer Research, Christian-Albrechts-University Kiel, 24105 Kiel, Germany;
- Correspondence: ; Tel.: +491605559588
| |
Collapse
|